FREQ - Frequency Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Frequency Therapeutics, Inc.

75 Hayden Avenue
Suite 300
Lexington, MA 02421
United States
781 315 4600

Full Time Employees46

Key Executives

NameTitlePayExercisedYear Born
Mr. David L. LucchinoCo-Founder, Pres, CEO & Director1.02MN/A1970
Dr. Christopher R. Loose Ph.D.Co­-Founder & Chief Scientific Officer687.73kN/A1981
Mr. Richard J. MitranoVP of Fin. & OperationsN/AN/A1971
Mr. James P. AbelyAssociate Gen. Counsel & Sec.N/AN/AN/A
Dr. Dana C. Hilt M.D.Chief Medical Officer (acting)N/AN/A1953
Dr. John L. LaMattina Ph.D.Sr. Advisor & Member of PCA Regenerative Medicine Advisory BoardN/AN/A1950
Dr. Quentin McCubbin Ph.D.Chief Manufacturing OfficerN/AN/A1970
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Frequency Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2023 is 10. The pillar scores are Audit: 3; Board: 10; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.